Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 3/20 | 0.39 |
| ▸ | FLT4 | P35916 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | VCP | P55072 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925668 | 0.90 | TRPV1 (0.46) | ALOX5TRPV1KITDGAT1FLT1 | |
| SCHEMBL22925582 | 0.89 | ALOX5 (0.53) | ALOX5TRPV1DGAT1FLT1FLT4 | |
| SCHEMBL24637048 | 0.88 | ALOX5 (0.55) | ALOX5TRPV1KITDGAT1FLT1 | |
| SCHEMBL22925577 | 0.86 | ALOX5 (0.53) | ALOX5TRPV1KITDGAT1FLT1 | |
| SCHEMBL29696307 | 0.83 | TRPV1 (0.46) | ALOX5TRPV1DGAT1FLT1FLT4 | |
| SCHEMBL22925770 | 0.83 | TRPV1 (0.46) | ALOX5TRPV1DGAT1FLT1FLT4 | |
| SCHEMBL22925573 | 0.82 | ALOX5 (0.41) | ALOX5TRPV1KITFLT1FLT4 | |
| SCHEMBL22925895 | 0.81 | ALOX5 (0.58) | ALOX5TRPV1KITFLT1FLT4 | |
| SCHEMBL22925665 | 0.78 | FLT1 (0.50) | ALOX5TRPV1FLT1FLT4KDR | |
| SCHEMBL29696294 | 0.78 | FLT1 (0.50) | ALOX5TRPV1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | ALOX5 1469/4885TRPV1 4690/4885KIT 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.